Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3120491
Max Phase: Preclinical
Molecular Formula: C48H66N6O10S
Molecular Weight: 919.15
Molecule Type: Small molecule
Associated Items:
ID: ALA3120491
Max Phase: Preclinical
Molecular Formula: C48H66N6O10S
Molecular Weight: 919.15
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C1CCCCC1)NC(=O)O[C@@H]1C[C@H]1CCCCCc1c(nc3ccccc3c1OCCCN1CCOCC1)O2)C(=O)NS(=O)(=O)C1(C)CC1
Standard InChI: InChI=1S/C48H66N6O10S/c1-3-33-29-48(33,45(57)52-65(59,60)47(2)19-20-47)51-42(55)38-28-34-30-54(38)44(56)40(31-13-6-4-7-14-31)50-46(58)64-39-27-32(39)15-8-5-9-17-36-41(62-24-12-21-53-22-25-61-26-23-53)35-16-10-11-18-37(35)49-43(36)63-34/h3,10-11,16,18,31-34,38-40H,1,4-9,12-15,17,19-30H2,2H3,(H,50,58)(H,51,55)(H,52,57)/t32-,33-,34-,38+,39-,40+,48-/m1/s1
Standard InChI Key: PLXZPANQGYHHNJ-ZJYDXQDKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 919.15 | Molecular Weight (Monoisotopic): 918.4561 | AlogP: 4.92 | #Rotatable Bonds: 12 |
Polar Surface Area: 194.80 | Molecular Species: ACID | HBA: 12 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 16 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 3.56 | CX Basic pKa: 7.10 | CX LogP: 3.88 | CX LogD: 4.14 |
Aromatic Rings: 2 | Heavy Atoms: 65 | QED Weighted: 0.19 | Np Likeness Score: 0.21 |
1. Shah U, Jayne C, Chackalamannil S, Velázquez F, Guo Z, Buevich A, Howe JA, Chase R, Soriano A, Agrawal S, Rudd MT, McCauley JA, Liverton NJ, Romano J, Bush K, Coleman PJ, Grisé-Bard C, Brochu MC, Charron S, Aulakh V, Bachand B, Beaulieu P, Zaghdane H, Bhat S, Han Y, Vacca JP, Davies IW, Weber AE, Venkatraman S.. (2014) Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors., 5 (3): [PMID:24900818] [10.1021/ml400466p] |
Source(1):